Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

NCT03935555 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Samus Therapeutics company closure

Conditions

Primary Myelofibrosis (PMF)
Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

DRUG: PU-H71

Sponsor

Samus Therapeutics, Inc.